1. Introduction and Background
Selank (TP-7) is a synthetic heptapeptide with the amino acid sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro (molecular weight 751.9 Da), developed at the Institute of Molecular Genetics of the Russian Academy of Sciences in collaboration with the V.V. Zakusov Research Institute of Pharmacology. The peptide was designed as a structural analogue of tuftsin, a naturally occurring tetrapeptide (Thr-Lys-Pro-Arg) that is cleaved from the Fc region of immunoglobulin G by the splenic enzyme tuftsinase. Tuftsin itself was first characterised in the 1970s as an endogenous immunostimulatory factor that enhances phagocytic activity of neutrophils and macrophages. However, its rapid enzymatic degradation in vivo severely limits its pharmacological utility (Kozlovskaya et al., 2003).
The addition of the C-terminal tripeptide extension (Pro-Gly-Pro) to the native tuftsin sequence was undertaken to confer enhanced proteolytic stability while preserving the biological activity of the parent molecule. This structural modification proved consequential beyond mere stabilisation: the resulting heptapeptide exhibited a distinct pharmacological profile that combined the immunomodulatory properties of tuftsin with novel anxiolytic and nootropic activities not observed with the parent tetrapeptide (Kozlovskaya et al., 2003). Selank has since been the subject of extensive preclinical investigation and limited clinical evaluation, primarily within Russian pharmacological research programmes.
2. Mechanism of Action
2.1 GABAergic Modulation
A substantial body of evidence indicates that Selank exerts its anxiolytic effects, at least in part, through modulation of the gamma-aminobutyric acid (GABA) neurotransmitter system. Volkova et al. (2016) demonstrated that Selank administration significantly altered the expression of genes encoding key components of the GABAergic signalling apparatus in the hippocampus of Wistar rats. Specifically, the study reported upregulation of genes encoding GABA transporter proteins and subunits of the GABAA receptor complex, suggesting that Selank enhances inhibitory neurotransmission through transcriptional mechanisms rather than direct receptor agonism (Volkova et al., 2016).
This gene-expression-level modulation distinguishes Selank mechanistically from classical benzodiazepine anxiolytics, which act as allosteric modulators at the GABAA receptor and produce their effects through immediate post-translational enhancement of chloride conductance. The transcriptional nature of Selank's GABAergic effects implies a slower onset but potentially more sustained modulation of inhibitory tone, and critically, a lower propensity for the tolerance, dependence, and sedation that characterise benzodiazepine pharmacology. Electrophysiological studies in rodent hippocampal preparations have corroborated these findings, demonstrating enhanced GABAergic inhibitory postsynaptic currents following Selank exposure without the characteristic sedative signatures associated with direct GABAA agonism.
2.2 Enkephalin Stabilisation
A second well-characterised mechanism through which Selank modulates central nervous system function involves the inhibition of enzymes responsible for the degradation of endogenous enkephalins. Kost et al. (2001) demonstrated that Selank inhibits carboxypeptidase activity and other peptidases involved in the metabolic inactivation of Leu-enkephalin and Met-enkephalin, thereby prolonging the half-life and bioavailability of these endogenous opioid peptides within the synaptic cleft (Kost et al., 2001).
Enkephalins are known to exert both analgesic and anxiolytic effects through activation of delta-opioid receptors and, to a lesser extent, mu-opioid receptors in limbic structures including the amygdala and nucleus accumbens. By stabilising endogenous enkephalin levels, Selank may produce anxiolytic effects through an indirect opioidergic mechanism that avoids the direct receptor activation and consequent tolerance development associated with exogenous opioid administration. This dual mechanism — simultaneous GABAergic enhancement and enkephalinase inhibition — has been proposed as the basis for Selank's robust anxiolytic profile observed across multiple behavioural paradigms (Kost et al., 2001).
3. Anxiolytic Research
The anxiolytic properties of Selank have been evaluated across a range of validated preclinical behavioural models. Kozlovskaya et al. (2003) reviewed the cumulative behavioural evidence for Selank and related short tuftsin-family peptides in the regulation of adaptive behaviour under stress, documenting anxiolytic activity across conflict-based and exploratory paradigms at doses that did not impair locomotor function or produce sedation (Kozlovskaya et al., 2003). This dissociation between anxiolytic efficacy and sedation is pharmacologically significant, as it suggests a wider therapeutic index relative to benzodiazepines, which characteristically suppress both anxiety and motor function within a narrow dose range.
Complementary studies utilising the elevated plus-maze, open field test, and conditioned avoidance paradigms have corroborated the anxiolytic profile of Selank. Kozlovskii and Danchev (2003) demonstrated that Selank optimised conditioned active avoidance performance in rats, an observation consistent with both anxiolytic and cognition-enhancing effects. Notably, the behavioural improvements exhibited an inverted U-shaped dose-response relationship, with moderate doses producing optimal effects and higher doses yielding diminished benefit (Kozlovskii and Danchev, 2003). This dose-response pattern is characteristic of peptidergic neuromodulators and has been interpreted as evidence for a homeostatic, rather than unidirectional, influence on neural circuit activity.
Preliminary clinical observations in patients with generalised anxiety disorder have suggested that Selank may reduce anxiety scores on standardised assessment instruments, although these findings derive primarily from open-label and small-sample studies conducted within the Russian clinical research literature. Medvedev et al. (2015) reported improvements in anxiety symptom scores among patients receiving Selank for generalised anxiety and related disorders, supporting its utility as an adjunctive or alternative treatment in clinically anxious populations (Medvedev et al., 2015). Large-scale, randomised, placebo-controlled trials conforming to international regulatory standards have not yet been published, and this represents a significant limitation of the current evidence base.
4. Immune Modulation
Consistent with its structural derivation from the immunostimulatory peptide tuftsin, Selank exhibits significant immunomodulatory activity. Kolomin et al. (2011) characterised the effects of Selank on inflammation-related gene expression in mouse spleen, demonstrating that the peptide modulates the transcriptional activity of genes encoding cytokines, chemokines, and other inflammatory mediators in a regulated and tissue-specific manner (Kolomin et al., 2011). Importantly, the immunomodulatory effects of Selank appear to be regulatory rather than uniformly stimulatory: the peptide has been observed to both enhance suppressed immune parameters and attenuate excessive inflammatory responses, depending on the baseline immunological state of the experimental system.
Kolomin et al. (2014) further delineated the immunological effects of Selank by examining the temporal dynamics of inflammation-related gene expression following peptide administration. The investigators documented that Selank produces time-dependent, bidirectional modulation of genes involved in innate and adaptive immunity, with distinct transcriptional patterns emerging at early versus later time points after dosing (Kolomin et al., 2014). These bidirectional immunomodulatory properties distinguish Selank from conventional immunostimulants and suggest a mechanism more consistent with immune homeostasis restoration than simple immune activation.
The intersection of immune and neurological effects is of particular interest in the context of psychoneuroimmunological research. The bidirectional communication between the hypothalamic-pituitary-adrenal axis and the immune system suggests that a peptide capable of modulating both anxiety-related neural circuits and immune function may exert complementary effects through convergent neuroendocrine pathways, a framework supported by clinical reports of concurrent anxiolytic and immunological improvements in patients receiving Selank (Syunyakov et al., 2012).
5. Current Research Directions and Limitations
Contemporary research on Selank encompasses several active lines of investigation. Genomic and transcriptomic approaches are being employed to further characterise the peptide's effects on gene expression within the central nervous system, building upon the initial GABAergic findings of Volkova et al. (2016). These studies have revealed that Selank's transcriptional influence extends beyond the GABA system to encompass genes involved in neurotrophic signalling, inflammatory regulation, and synaptic plasticity, suggesting a broader neurobiological footprint than initially appreciated (Volkova et al., 2016).
Investigation of Selank's potential neuroprotective properties constitutes another active research area. Preclinical data have suggested protective effects against oxidative stress-induced neuronal damage and excitotoxicity in cell culture models, although the in vivo relevance of these observations requires further validation. The peptide's ability to modulate brain-derived neurotrophic factor (BDNF) expression has also attracted interest, given the established role of BDNF in neuronal survival, synaptic plasticity, and the pathophysiology of mood and anxiety disorders.
Several important limitations constrain the current interpretation of Selank research. The published literature is heavily concentrated within Russian-language journals and research institutions, which limits both accessibility and independent verification by the broader international scientific community. While the pharmacological data are internally consistent across numerous studies, large-scale replication by independent international research groups remains limited. Furthermore, the clinical evidence base, while suggestive of anxiolytic efficacy, lacks the rigorous controlled trial methodology that would be required for regulatory approval in Western jurisdictions.
Pharmacokinetic characterisation of Selank in humans remains incomplete, with limited published data on bioavailability, tissue distribution, and metabolic fate following various routes of administration. The peptide has been investigated primarily via intranasal delivery, which bypasses first-pass hepatic metabolism and may provide preferential access to central nervous system targets, although the precise extent of brain penetration following intranasal administration has not been definitively established.
In summary, Selank represents a structurally novel tuftsin-derived heptapeptide with a distinctive dual pharmacological profile encompassing both anxiolytic and immunomodulatory properties. Its mechanism of action, involving GABAergic transcriptional modulation and enkephalinase inhibition, differentiates it from classical anxiolytic agents and positions it as a compound of interest for research into peptidergic approaches to anxiety and neuroimmune regulation. The translation of the existing preclinical and preliminary clinical evidence into a robust, internationally validated evidence base remains the principal challenge for future Selank research.